Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Company Overview

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $2.43 to $2.51
• 50-Day Range: $2.45 to $3.46
• 52-Week Range: $2.11 to $285.00
• Volume: 30,742 shs
• Average Volume: 50,937 shs
• Market Capitalization: $3.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Sunshine Biopharma Stock Analysis - MarketRank™

Sunshine Biopharma scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sunshine Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sunshine Biopharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sunshine Biopharma is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.08% of the float of Sunshine Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sunshine Biopharma has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sunshine Biopharma does not currently pay a dividend.

Dividend Growth

Sunshine Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.08% of the float of Sunshine Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sunshine Biopharma has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

Percentage Held by Institutions

41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SBFM Stock Analysis - Frequently Asked Questions

How have SBFM shares performed this year?

Sunshine Biopharma's stock was trading at $3.00 at the beginning of the year. Since then, SBFM stock has decreased by 18.3% and is now trading at $2.45.
View the best growth stocks for 2025 here.

How were Sunshine Biopharma's earnings last quarter?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its earnings results on Tuesday, November, 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of $9.00 by $9.94. The firm earned $8.44 million during the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 17.89% and a negative net margin of 12.82%.

When did Sunshine Biopharma's stock split?

Sunshine Biopharma shares reverse split on Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Sunshine Biopharma's major shareholders?

Top institutional shareholders of Sunshine Biopharma include Connective Capital Management LLC (0.93%). Insiders that own company stock include Camille Sebaaly and Steve N Slilaty.
View institutional ownership trends.

How do I buy shares of Sunshine Biopharma?

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sunshine Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SBFM
• CUSIP: N/A
• CIK: 1402328
• Web: www.sunshinebiopharma.com
• Phone: (514) 426-6161
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +512.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($150.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,510,000.00
• Net Margins: -12.82%
• Pretax Margin: -12.48%
• Return on Equity: -17.89%
• Return on Assets: -14.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.74
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: $32.96 million
• Price / Sales: 0.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1,651.69 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,224,000
• Free Float: 1,223,000
• Market Cap: $3.00 million
• Optionable: Not Optionable
• Beta: 1.33